Clinical trials are ongoing to evaluate the single dose escalation safety and efficacy outcomes of CD38 CAR-T-cell therapy in relapsed or refractory MM patients (NCT03464916 and NCT03767751). The gene discussed is CD38; the disease is Miyoshi myopathy.